In a June 12 conference at UW-Madison, researchers gathered from across the U.S. and abroad to discuss the latest progress on TDP-43 biomarkers. In all, 74 people attended in person, and 727 virtually ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

Ever since loss-of-function variants in the gene for PILRA, short for paired immunoglobulin-like type 2 receptor alpha, turned up as protecting against Alzheimer’s disease, scientists have wondered ...

Series - AD/PD™ 2024: Advances in Science & Therapy: Part 1 of 9: Fast Plaque Clearance with Little ARIA? So Teases Trontinemab at AD/PD 2024 Part 2 of 9: TauRx Parses Subgroups to Make the Case for ...

Studies aim to validate Alzheimer's disease blood tests against gold standard biomarkers in primary care. Scientists ask how best to incorporate AD blood tests into existing healthcare systems. Some ...

In mice, APOE3-Christchurch reduced amyloidosis, tauopathy, and tau spreading. Two copies of APOE4-Christchurch staved off tangles, gliosis, and neurodegeneration. Just one copy reduced gliosis and ...

Scientists reported results of a round-robin comparison of more than two dozen plasma phospho-tau assays. (Hint: p-tau 217 tests outdid the rest of the flock.) A clearer picture emerged of how plasma ...

The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more ...

Joachim Herz of the University of Texas Southwestern Medical Center, Dallas, who has studied Reelin in the brain for decades, was unsurprised that a variant was protective, though the magnitude of ...

Michelle Mielke at Wake Forest University in Winston-Salem, North Carolina, noted that women’s higher risk is likely to have multiple causes. “Hormones are a contributor, but there are a lot of other ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...